Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2024.
Search results for: pain
Fun in the Sun: The Benefits of Vitamin D
Vitamin D has gotten a lot of press over the years. But is it actually worth the hype, especially when it comes to autoimmunity? Does it prevent the onset of autoimmune disease? Does it have a role in treatment? Experts in this ACR Convergence 2024 session helped decipher the role of vitamin D in bone health, immune regulation and infection reduction.
SURF’n Autoinflammation: Evaluation & Management of Syndrome of Undifferentiated Recurrent Fever
At this ACR Convergence 2024 session, the focus was on the identification & treatment of a newly identified syndrome of undifferentiated recurrent fever (SURF).
Should We Manage Men & Women Differently?
Experts address how sex differences affect the clinical presentation, diagnosis, response to therapy and experience of illness for patients with PsA.
Advancements in Imaging
Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.
Better Education on Gout
Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.
Approaches to Difficult-to-Manage Spondyloarthritis
At this ACR Convergence 2024 session, two experts spoke about identifying difficult-to-manage patients with spondyloarthritis, differentiating active disease from fibromyalgia & therapy selection in these patients.
A More Equitable Future in Lupus Care & Outcomes
The 2024 Dubois Memorial Lecture focused on health inequities with lupus & strategies to close the gap.
Risky Business: Understanding What It Means to Be at Risk for RA
The goal is to identify people at risk for RA &, perhaps, prevent its onset.
The Management of Psoriatic Arthritis: A Review
WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 249
- Next Page »